BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ZP6590 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ZP6590\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07721597-164@assetmemo.bio
DTSTAMP:20261121T005304Z
DTSTART;VALUE=DATE:20270906
DTEND;VALUE=DATE:20270907
SUMMARY:ZP6590: Phase 1 readout est. (NCT07721597)
DESCRIPTION:ZP6590\, phase 1\, Obesity.\nStudy: A Single and Multiple Ascen
 ding Dose Trial Assessing Safety\, Tolerability\, Pharmacokinetics and Pha
 rmacodynamics of ZP6590 in Participants With Normal Weight\, Overweight an
 d Obesity\nEstimated primary completion: 6 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zp6590#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07721597
URL:https://assetmemo.bio/drug/zp6590#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
